PAS蛋白融合修饰研究进展

doi:10.13560/j.cnki.biotech.bull.1985.2019-0519

摘要/Abstract

摘要： PAS蛋白修饰技术是指通过基因融合的方法将具有功能性的多肽与由脯氨酸、丙氨酸和丝氨酸组成的多肽序列连接起来并通过基因工程的手段进行融合表达,实现对多肽的修饰。目前,对于小分子多肽类药物而言,其较小的体积导致在血浆中的半衰期较短,而临床上应用PEG对小分子多肽药物进行修饰,使得其具有较大的流体力学体积,增加其药理活性。但是近年来,随着越来越多的PEG修饰药物进入临床应用市场,PEG化学多聚物的安全性弊端被不断发现。因此,寻找PEG化以外的更为安全有效的方法是非常有必要的,而PAS在小分子多肽修饰方面展示出了巨大的优势。就针对于PAS蛋白修饰技术的设计思路和优势,以及在应用方面取得的最新进展进行具体的阐述。

关键词: PAS蛋白修饰技术, 融合表达, 半衰期, 优势, 应用

Abstract: PAS protein modification technology refers to that functional polypeptides with polypeptide sequences composed of proline,alanine and serine by gene fusion are linked and fusion expression is conducted by gene engineering,thus polypeptide modification is achieved. At present,for small molecule polypeptide drugs,its smaller volume leads to a shorter half-life in plasma,and the clinical application of PEG to modify small molecule polypeptide drugs makes it have a larger hydrodynamic volume and thus its pharmacological activity is increased. However,with more and more PEG modified drugs entering the clinical application market in recent years,the safety drawbacks of PEG chemical polymers have been constantly uncovered. Therefore,it is necessary to seek more safe and effective methods besides PEG modification,and PAS has shown great advantages in small molecular polypeptide modification. In this paper,the design ideas and advantages of PAS protein modification technology,as well as the latest progress in application are described in detail.

Key words: PASylation, fusion expression, half-life, advantages, application

韩斐, 江明锋, 冉嫆, 王刚. PAS蛋白融合修饰研究进展[J]. 生物技术通报, 2019, 35(12): 152-158.

HAN Fei, JIANG Ming-feng, RAN Rong, WANG Gang. Research Progress in Fusion Modification of PAS[J]. Biotechnology Bulletin, 2019, 35(12): 152-158.

参考文献

[1] Kinch, Michael S.An overview of FDA-approved biologics medicines[J]. Drug Discovery Today, 2015, 20(4):393-398.
[2] Meibohm B, Zhou H.Characterizing the impact of renal impairment on the clinical pharmacology of biologics[J]. Journal of Clinical Pharmacology, 2012, 52(S1):54S-62S.
[3] Corsetti M, Tack J.Naloxegol:The first orally administered, peripherally acting, μ opioid receptor antagonist, approved for the treatment of opioid-induced constipation[J]. Drugs of Today(Barc), 2015, 51(8):479-489.
[4] Gabizon AA, Patil Y, La-Beck NM.New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy[J]. Drug Resistance Updates, 2016, 29:90-106.
[5] Turecek PL, Bossard MJ, Schoetens F, et al.PEGylation of biopharmaceuticals:a review of chemistry and nonclinical safety information of approved drugs[J]. Journal of Pharmaceutical Sciences, 2016, 105(2):460-475.
[6] Bendele A, Seely J, Richey C, et al.Short Communication:Renal tubular vacuolation in animals treated with Polyethylene-Glycol-Conjugated proteins[J]. Toxicological Sciences, 1998, 42(2):152-157.
[7] Armstrong JK, Hempel G, Koling S, et al.Antibody against poly(ethylene glycol)adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients[J]. Cancer, 2010, 110(1):103-111.
[8] Ganson NJ, Kelly SJ, Scarlett E, et al.Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol)(PEG), in a phase I trial of subcutaneous PEGylated urate oxidase[J]. Arthritis Research & Therapy, 2005, 8(1):R12.
[9] Hershfield MS, Ganson NJ, Kelly SJ, et al.Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients[J]. Arthritis Research & Therapy, 2014, 16(2):R63.
[10] Judge A, Mcclintock K, Phelps J, et al.Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes[J]. Molecular Therapy, 2006, 13(2):328-337.
[11] Schlapschy M, Binder U, Borger C, et al.PASylation:a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins[J]. Protein Engineering Design and Selection, 2013, 26(8):489-501.
[12] Breibeck J, Skerra A.The polypeptide biophysics of proline/alanine-rich sequences(PAS):Recombinant biopolymers with PEG-like properties[J]. Biopolymers, 2017:e23069.
[13] Binder U, Skerra A.PASylation:A versatile technology to extend drug delivery[J]. Current Opinion in Colloid & Interface Science, 2017, 31:10-17.
[14] Nanda P, JagadeeshBabu PE, Raju JR. Production and optimization of site-specific monoPEGylated uricase conjugates using mPEG-maleimide through RP-HPLC methodology[J]. Journal of Pharmaceutical Innovation, 2016, 11(4):279-288.
[15] Pfister D, Morbidelli M.Process for protein PEGylation[J]. Journal of Controlled Release, 2014, 180:134-149.
[16] Bailon P, Palleroni A, Schaffer CA, et al.Rational design of a potent, long-lasting form of interferon:A 40 kD branched polyethylene glycol-conjugated interferon α-2a for the treatment of Hepatitis C[J]. Bioconjugate Chemistry, 2001, 12(2):195-202.
[17] Yu P, Zheng C, Chen J, et al.Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist[J]. Bioorganic and Medicinal Chemistry, 2007, 15(16):5396-5405.
[18] Kuhn N, Schmidt CQ, Schlapschy M, et al.PASylated Coversin, a C5-specific complement inhibitor with extended pharmacokinetics, shows enhanced antihemolytic activity in vitro[J]. Bioconjugate Chemistry, 2016, 27:2359-2371.
[19] Morath V, Bolze F, Schlapschy M, et al.PASylation of murine leptin leads to extended plasma half-life and enhanced in vivo efficacy[J]. Molecular Pharmaceutics, 2015, 12(5):1431-1432.
[20] Pasut G, Veronese FM.State of the art in PEGylation:the great versatility achieved after forty years of research[J]. Journal of Controlled Release, 2012, 161(2):461-472.
[21] Deeks ED.Certolizumab Pegol:A review in inflammatory autoimmune diseases[J]. BioDrugs, 2016, 30(6):607-617.
[22] Ivens IA, Achanzar W, Baumann A, et al.PEGylated biopharmaceuticals:current experience and considerations for nonclinical development[J]. Toxicologic Pathology, 2015, 43:959-983.
[23] Luo X, Hou L, Liang L, et al.Long-acting PEGylated recombinant human growth hormone(Jintrolong)for children with growth hormone deficiency:phase II and phase III multicenter, randomized studies[J]. European Journal of Endocrinology, 2017, 177(2):195-205.
[24] Di CS, Binder U, Maier T, et al.High-yield production of PASylated human growth hormone using secretory E. coli technology[J]. BioProcess International Magazine, 2013, 11:30-80.
[25] Zvonova EA, Ershov AV, Ershova OA, et al.PASylation technology improves recombinant interferon-β1b solubility, stability, and biological activity[J]. Applied Microbiology and Biotechnology, 2017, 101(5):1975-1987.
[26] Bolze F, Morath V, Bast A, et al.Long-Acting PASylated leptin ameliorates obesity by promoting satiety and preventing hypometabolism in leptin-deficient lep(ob/ob)mice[J]. Endocrinology, 2016, 157:233-244.
[27] Hedayati MH, Norouzian D, Aminian M, et al.Molecular design, expression and evaluation of PASylated human recombinant erythropoietin with enhanced functional properties[J]. The Protein Journal, 2017, 36(1):36-48.
[28] Nelson AL, Reichert JM.Development trends for therapeutic antibody fragments[J]. Nature Biotechnology, 2009, 27(4):331-337.
[29] Reichert JM.Marketed therapeutic antibodies compendium[J]. MAbs, 2012, 4:413-415.
[30] Holliger P, Hudson PJ.Engineered antibody fragments and the rise of single domains[J]. Nature Biotechnology, 2005, 23(9):1126-1136.
[31] Dennis MS, Jin H, Dugger D, et al.Imaging tumors with an albumin-binding fab, a novel tumor-targeting agent[J]. Cancer Research, 2007, 67(1):254-261.
[32] Thurber GM, Zajic SC, Wittrup KD.Theoretic criteria for antibody penetration into solid tumors and micrometastases[J]. Journal of Nuclear Medicine, 2007, 48(6):995-999.
[33] Mendler CT, Friedrich L, Laitinen I, et al.High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation[J]. MAbs, 2015, 7(1):96-109.
[34] Falvo E, Tremante E, Arcovito A, et al.Improved doxorubicin encapsulation and pharmacokinetics of ferritinfusion protein nanocarriers bearing proline, serine, and alanine elements[J]. Biomacromolecules, 2016, 17(2):514-522.
[35] 曹阳, 包永明, 安利佳, 等. 乳铁蛋白研究现状[J]. 食品科学, 2002, 23(12):132-138.
[36] Lerchner A, Daake M, Jarasch A, et al.Fusion of an alcohol dehydrogenase with an aminotransferase using a PAS linker to improve coupled enzymatic alcohol-to-amine conversion[J]. Protein Engineering Design and Selection, 2016, 29(12):557-562.
[37] Sadry SA, Drucker DJ.Emerging combinatorial hormone therapies for the treatment of obesity and T2DM[J]. Nature Reviews Endocrinology, 2013, 9(7):425-433.
[38] Kontermann RE.Half-life extended biotherapeutics[J]. Expert Opinion on Biological Therapy, 2016, 16:903-915.
[39] Huang YS, Wen XF, Wu YL, et al.Engineering a pharmacologically superior form of granulocyte-colony-stimulating factor by fusion with gelatin-like-protein polymer[J]. European Journal of Pharmaceutics & Biopharmaceutics, 2010, 74:435-441.
[40] Olsen D, Yang C, Bodo M, et al.Recombinant collagen and gelatin for drug delivery[J]. Advanced Drug Delivery Reviews, 2003, 55(12):1547-1567.
[41] Cleland JL, Geething NC, Moore JA, et al.A novel long-acting human growth hormone fusion protein(vrs-317):enhanced in vivo potency and half-life[J]. Journal of Pharmaceutical Sciences, 2012, 101(8):2744-2754.
[42] Podust VN, Balan S, Sim BC, et al.Extension of in vivo half-life of biologically active molecules by XTEN protein polymers[J]. Journal of Controlled Release, 2016, 240:52-66.
[43] Geething NC, To W, Spink BJ, et al.Gcg-XTEN:An improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose[J]. PLoS One, 2010, 5(4):e10175.
[44] Alters SE, Mclaughlin B, Spink B, et al.GLP2-2G-XTEN:a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn’s[J]. PLoS One, 2012, 7(11):e50630.
[45] Bain V.A phase 2 study to assess antiviral response, safety, and pharmacokinetics of Albuferon^ in IFN-alfa naive subjects with genotype 1 chronic hepatitis C[J]. Journal of Hepatology, 2005, 42(Suppl 2):9.
[46] Sato C, Kitajima K.Polysialic acid[J]. Glycoscience Biology & Medicine, 2014:519-528.